Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Adial Pharmaceuticals, Inc. (ADIL)

Compare
0.6860
-0.0309
(-4.31%)
At close: April 17 at 4:00:01 PM EDT
0.7298
+0.04
+(6.38%)
After hours: April 17 at 5:28:55 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
8,284.4570
8,284.4570
--
10,859.4750
17,740.3260
Operating Income
-8,284.4570
-8,284.4570
--
-10,859.4750
-17,740.3260
Net Non Operating Interest Income Expense
178.6590
178.6590
--
63.3380
6.5390
Other Income Expense
-5,091.6530
-5,091.6530
--
522
-1,783.6160
Pretax Income
-13,197.4510
-13,197.4510
--
-10,796.1370
-19,517.4030
Tax Provision
--
--
--
--
-94.0770
Net Income Common Stockholders
-13,197.4510
-13,197.4510
--
-12,731.4160
-19,423.3260
Diluted NI Available to Com Stockholders
-13,197.4510
-13,197.4510
--
-12,731.4160
-19,423.3260
Basic EPS
-2.72
--
-3.60
-12.71
-26.00
Diluted EPS
-2.72
--
-3.60
-12.71
-26.00
Basic Average Shares
4,851.4870
--
1,424.6610
1,001.5050
743.5490
Diluted Average Shares
4,851.4870
--
1,424.6610
1,001.5050
743.5490
Total Operating Income as Reported
-8,284.4570
-8,284.4570
--
-10,859.4750
-19,288.7230
Total Expenses
8,284.4570
8,284.4570
--
10,859.4750
17,740.3260
Net Income from Continuing & Discontinued Operation
-13,197.4510
-13,197.4510
--
-12,731.4160
-19,423.3260
Normalized Income
-8,733.0240
-8,733.0240
--
-10,796.1370
-17,602.0005
Interest Income
178.6590
178.6590
--
63.3380
6.5390
Net Interest Income
178.6590
178.6590
--
63.3380
6.5390
EBIT
-8,284.4570
-8,284.4570
--
-10,859.4750
-17,740.3260
EBITDA
-8,283.8920
-8,283.8920
--
-10,858.9110
-17,685.2200
Reconciled Depreciation
0.5650
0.5650
--
0.5640
55.1060
Net Income from Continuing Operation Net Minority Interest
-13,197.4510
-13,197.4510
--
-10,796.1370
-19,423.3260
Total Unusual Items Excluding Goodwill
-4,464.4270
-4,464.4270
--
522
-1,830.1100
Total Unusual Items
-4,464.4270
-4,464.4270
--
522
-1,830.1100
Normalized EBITDA
-3,819.4650
-3,819.4650
--
-10,858.9110
-15,855.1100
Tax Rate for Calcs
--
--
--
--
0
Tax Effect of Unusual Items
--
--
--
--
-8.7845
12/31/2021 - 7/27/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

REVB Revelation Biosciences, Inc.
3.0800
+2.67%
 
XBIO Xenetic Biosciences, Inc.
2.4315
+0.89%
 
DRMA Dermata Therapeutics, Inc.
0.7290
+1.25%
 
PXMD PaxMedica, Inc.
0.0001
0.00%
 
BPTH Bio-Path Holdings, Inc.
0.1697
+25.24%
 
ATHE Alterity Therapeutics Limited
3.5000
+4.17%
 
AZTR Azitra, Inc.
0.2850
-10.38%
 
SLRX Salarius Pharmaceuticals, Inc.
0.6770
+1.04%
 
SPRC SciSparc Ltd.
0.2826
+4.24%
 
HOTH Hoth Therapeutics, Inc.
0.7876
+1.78%